Why the study?
Despite advancements in MCS devices, mortality for cardiogenic shock remains high, leaving the efficacy of early IABP support versus medical therapy in AMI-CS with severe LV systolic dysfunction unclear.
Does early intra-aortic balloon pump support reduce in-hospital mortality in patients with cardiogenic shock complicating acute myocardial infarction and severe LV dysfunction?
Does early intra-aortic balloon pump support reduce in-hospital mortality in patients with cardiogenic shock complicating acute myocardial infarction and severe LV dysfunction?
While overall IABP use did not significantly reduce mortality, early initiation within 2 hours of shock onset was associated with lower in-hospital mortality and reduced need for advanced mechanical circulatory support in AMI-CS patients with severe LV dysfunction.
May warrant early IABP in AMI-CS with severe LV dysfunction; extends neutral overall evidence by suggesting timing is critical yet requires RCT validation.
Background: Despite advancements in mechanical support (MCS) devices, the mortality rate for patients with cardiogenic shock remains high. This study aimed to evaluate the efficacy of early intra-aortic balloon pump (IABP) support compared to medical therapy in patients with cardiogenic shock (CS) due to acute myocardial infarction (AMI) (AMI-CS) resulting in severe left ventricular (LV) systolic dysfunction. Methods: We analyzed the RESCUE I registry (NCT02985008), a multicenter cohort of 1247 cardiogenic shock patients. A total of 192 patients with AMI-CS with LVEF ≤ 35% received either medical therapy (n = 105) or IABP support (n = 87) after shock development. The primary outcome was in-hospital mortality. Then, we compared mortality in early IABP initiation (shock-to-IABP < 2 h) to medical therapy. Results: The overall in-hospital mortality rate was 42.2%. While the difference in mortality rates between the medical therapy group and the IABP group was not statistically significant (47.6% vs. 35.6%, respectively, p = 0.094), a reduction in mortality was observed when IABP support was initiated within 2 h of shock onset (32.0% vs. 47.6%, p = 0.036). Furthermore, the need for advanced MCS was reduced in the IABP group compared to the medical group (4.6% vs. 22.9%, respectively, p < 0.001). Conclusions: In patients with AMI-CS and severe LV dysfunction, early IABP support initiated within 2 h of shock onset was associated with lower in-hospital mortality and reduced need for advanced MCS. These findings highlight the critical importance of timing rather than routine use, supporting a selective strategy for early IABP.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: